VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis
FRA:VX1 - Deutsche Boerse Ag - US92532F1003 - Common Stock - Currency: EUR
Overall VX1 gets a fundamental rating of 6 out of 10. We evaluated VX1 against 65 industry peers in the Biotechnology industry. VX1 is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VX1 has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year VX1 has reported negative net income.
In the past year VX1 has reported a negative cash flow from operations.
Of the past 5 years VX1 4 years were profitable.
VX1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
VX1 has a better Return On Assets (-4.32%) than 63.08% of its industry peers.
VX1 has a Return On Equity of -5.99%. This is in the better half of the industry: VX1 outperforms 67.69% of its industry peers.
VX1 has a better Return On Invested Capital (15.51%) than 92.31% of its industry peers.
VX1 had an Average Return On Invested Capital over the past 3 years of 17.35%. This is significantly above the industry average of 12.12%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.32% | ||
| ROE | -5.99% | ||
| ROIC | 15.51% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.35%
ROIC(5y)17.95%
1.3 Margins
The Operating Margin of VX1 (37.91%) is better than 93.85% of its industry peers.
VX1's Operating Margin has improved in the last couple of years.
VX1's Gross Margin of 86.03% is fine compared to the rest of the industry. VX1 outperforms 80.00% of its industry peers.
In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 37.91% | ||
| PM (TTM) | N/A | ||
| GM | 86.03% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VX1 is creating value.
VX1 has less shares outstanding than it did 1 year ago.
The number of shares outstanding for VX1 has been reduced compared to 5 years ago.
The debt/assets ratio for VX1 has been reduced compared to a year ago.
2.2 Solvency
VX1 has an Altman-Z score of 13.14. This indicates that VX1 is financially healthy and has little risk of bankruptcy at the moment.
VX1 has a Altman-Z score of 13.14. This is amongst the best in the industry. VX1 outperforms 93.85% of its industry peers.
VX1 has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
VX1 has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. VX1 outperforms 81.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 13.14 |
ROIC/WACC1.74
WACC8.93%
2.3 Liquidity
VX1 has a Current Ratio of 2.65. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
VX1 has a Current ratio of 2.65. This is comparable to the rest of the industry: VX1 outperforms 60.00% of its industry peers.
VX1 has a Quick Ratio of 2.29. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
VX1 has a Quick ratio of 2.29. This is comparable to the rest of the industry: VX1 outperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.65 | ||
| Quick Ratio | 2.29 |
3. Growth
3.1 Past
The earnings per share for VX1 have decreased strongly by -102.42% in the last year.
The earnings per share for VX1 have been decreasing by -44.14% on average. This is quite bad
VX1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.98%.
VX1 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.50% yearly.
EPS 1Y (TTM)-102.42%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%-14.71%
Revenue 1Y (TTM)8.98%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%2.96%
3.2 Future
Based on estimates for the next years, VX1 will show a very strong growth in Earnings Per Share. The EPS will grow by 152.83% on average per year.
VX1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.19% yearly.
EPS Next Y6218.78%
EPS Next 2Y751.41%
EPS Next 3Y331.01%
EPS Next 5Y152.83%
Revenue Next Year9.62%
Revenue Next 2Y10.15%
Revenue Next 3Y9.78%
Revenue Next 5Y10.19%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VX1. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 21.86, which indicates a rather expensive current valuation of VX1.
Based on the Price/Forward Earnings ratio, VX1 is valued cheaply inside the industry as 84.62% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.90, VX1 is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.86 |
4.2 Price Multiples
VX1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. VX1 is cheaper than 75.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 25.04 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of VX1 may justify a higher PE ratio.
A more expensive valuation may be justified as VX1's earnings are expected to grow with 331.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y751.41%
EPS Next 3Y331.01%
5. Dividend
5.1 Amount
No dividends for VX1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:VX1 (7/3/2025, 7:00:00 PM)
390.1
+2.5 (+0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.73%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap100.18B
Analysts75
Price Target447.04 (14.6%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.13%
Min EPS beat(2)-7.2%
Max EPS beat(2)-3.07%
EPS beat(4)1
Avg EPS beat(4)-133.54%
Min EPS beat(4)-527.57%
Max EPS beat(4)3.69%
EPS beat(8)4
Avg EPS beat(8)-65%
EPS beat(12)7
Avg EPS beat(12)-42.16%
EPS beat(16)10
Avg EPS beat(16)-29.51%
Revenue beat(2)1
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)2.68%
Revenue beat(4)1
Avg Revenue beat(4)-1.23%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.75%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)8
Avg Revenue beat(16)0.2%
PT rev (1m)-2.55%
PT rev (3m)-4.19%
EPS NQ rev (1m)0.23%
EPS NQ rev (3m)-1.25%
EPS NY rev (1m)0.32%
EPS NY rev (3m)-0.64%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)-0.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.86 | ||
| P/S | 10.63 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.15 | ||
| P/tB | 7.89 | ||
| EV/EBITDA | 25.04 |
EPS(TTM)-0.35
EYN/A
EPS(NY)17.84
Fwd EY4.57%
FCF(TTM)-4.16
FCFYN/A
OCF(TTM)-3.24
OCFYN/A
SpS36.69
BVpS54.52
TBVpS49.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.32% | ||
| ROE | -5.99% | ||
| ROCE | 22.04% | ||
| ROIC | 15.51% | ||
| ROICexc | 22.97% | ||
| ROICexgc | 26.06% | ||
| OM | 37.91% | ||
| PM (TTM) | N/A | ||
| GM | 86.03% | ||
| FCFM | N/A |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.35%
ROIC(5y)17.95%
ROICexc(3y)45.4%
ROICexc(5y)50.15%
ROICexgc(3y)65.51%
ROICexgc(5y)78.06%
ROCE(3y)24.64%
ROCE(5y)25.5%
ROICexcg growth 3Y-26.3%
ROICexcg growth 5Y-6.95%
ROICexc growth 3Y-19.26%
ROICexc growth 5Y0.61%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score4
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.03 | ||
| Cap/Depr | 137.41% | ||
| Cap/Sales | 2.5% | ||
| Interest Coverage | 181.38 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.65 | ||
| Quick Ratio | 2.29 | ||
| Altman-Z | 13.14 |
F-Score4
WACC8.93%
ROIC/WACC1.74
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.84%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-102.42%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%-14.71%
EPS Next Y6218.78%
EPS Next 2Y751.41%
EPS Next 3Y331.01%
EPS Next 5Y152.83%
Revenue 1Y (TTM)8.98%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%2.96%
Revenue Next Year9.62%
Revenue Next 2Y10.15%
Revenue Next 3Y9.78%
Revenue Next 5Y10.19%
EBIT growth 1Y-1.84%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year827.23%
EBIT Next 3Y131%
EBIT Next 5Y70.83%
FCF growth 1Y-132.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-124.06%
OCF growth 3YN/A
OCF growth 5YN/A